You are here:
Home
NICE Guidance
Population groups
Children and teenagers
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development
Reference number:
GID-TA10638
Expected publication date: TBC
Project information
Project documents
Documents
Documents created during the development process.
Notes
Note
Note
Note
Back to top